glp 1 receptor agonists are contraindicated in Frontiers GLP-1 Receptor Agonists as Treatments
Description
Acknowledgments The authors gratefully acknowledge the critical reviews and insights of Sarah Armstrong MD, Nancie MacIver MD PhD, and Lisa Rasbach PhD CPNP
Clinical potential of fasting in type 1 diabetes
however, agents such as insulin or sulfonylureas increase hypoglycemia risk compared to placebo (48) and when used concomitantly with GLP-1 receptor agonists (1318)
But they had limitations: short timelines, selective populations, and controlled conditions
These medications represent the direct pharmaceutical descendants of the original lizard venom discovery
